Select Publications
With the goal of enhancing collaboration between the public and private R&D sectors, Barbara publishes analysis on topics related to drug and vaccine development driven by both companies and nonprofit organisations. Academically, Barbara is monitoring the emergence of new public private partnership models and assessing the resilience of existing cross-sector clinical R&D programmes to changes in development funding and health policy since 2015. Sub-analysis and observations associated with this investigation are featured in the site's blog.
Hope for control of centuries old epidemic
The pipeline of therapeutics and vaccines to treat or prevent tuberculosis is postured to bring one of humanity’s oldest and deadliest infectious diseases under control.
Nat Med. 2026 May;32(5):1560-1562 doi: 10.1038/d41591-026-00019-1.
The patient is now in the room
Patient-driven therapeutic development, once relegated to the realm of rare diseases is moving into the mainstream.
Nat Med. 2026 Apr;32(4):1166-1169. doi: 10.1038/s41591-026-04335-4.
First orexin agonists address root cause of narcolepsy
A new class of agents is poised to transform treatment for people with narcolepsy. Credited with discovering the gene for narcolepsy and making the link to the absence of orexin in narcolepsy patients, Emmanuel Mignot, a practicing psychiatrist and Professor of Sleep Medicine at Stanford University, cultivated the research base fostering multiple clinical discovery platforms developing OX2R agonists.
Non-profits wade in where for-profit life science investment
fears to tread
For decades, and in the exceptional instance of the Institut Pasteur for over a century, non-profit organisations continuously advance affordable and accessible pipelines of vaccines, medicines and diagnostics in the biopharmaceutical ecosystem.
Nat Biotechnol 2025 Aug;43(8):1221-1226. doi: 10.1038/s41587-025-02752-3.
The WHO aims for financial stability despite US exit
The World Health Organization’s inaugural Investment Round aims to instill stability in the face of global health headwinds and a US exit.
Nat Med 2025 Apr;31(4):1042-1044. doi: 10.1038/s41591-025-03649-z
Spotlight Analysis
